ERBB2 and neoplasm: In our study the probability of pCR was higher, even if statistically not significant, in the case of hormone receptor-negative tumours (25 vs 9.7%), Mib-1 ⩾20% (17.4 vs 7.7%) and Her-2 overexpression (20 vs 4%).